Wararka
Daaweynta laba-geesoodka ah ee BIOOCUS Medical Group waxay soo bandhigaysaa natiijooyin rajo leh oo ku saabsan Myasthenia Gravis oo aan fiicnayn: Safarka Bukaanka Da'da yar
Bukaan u dhashay Australia ayaa ku guuleystay jawaab celin hore oo cajiib ah iyadoo la adeegsanayo Daaweynta Dual CD19/CD20 CAR-T ee BIOOCUS Medical Group ee loogu talagalay DLBCL-ka soo noqnoqda
Muhiimadda La Socodka iyo Baaritaanka Joogtada ah ka dib Beerista Unugyada Jirka ee Hematopoietic
Dabagalka ka dib tallaalka waa mid muhiim u ah bukaanada tallaalka unugyada asliga ah ee dhiigga ku jira (HSCT). Baaritaannada joogtada ah waxay gacan ka geystaan sidii loo ogaan lahaa arrimaha sida caabuqyada, cudurka tallaalka ka soo horjeeda (GVHD), iyo dib u soo noqoshada, taasoo hubinaysa faragelinta hore iyo natiijooyin wanaagsan.
Daaweynta CAR-T waxay ka gudubtay saadaasha liidata ee Lymphoma-ka Unugga B ee Heerka Sare
Daraasad cusub ayaa muujinaysa in daaweynta CAR-T ay wanaajin karto saadaasha bukaanada qaba lymphoma-ka B-cell ee heerka sare ah (HGBL), oo ah nooc ka mid ah lymphoma-ka B-cell ee waaweyn, xitaa khadadka daaweynta ee dambe, taasoo siinaysa rajo cusub kiisaskan adag.
Faragelinta Hore ee Daaweynta CAR-T ee loogu talagalay Lymphoma-ka Unugyada B ee Weyn waxay Muujisaa Natiijooyin Rajo leh
Daraasad dib-u-eegis ah oo isbarbardhigaysa daaweynta CAR-T ee hore iyo kan dambe ee bukaanada waaweyn ee lymphoma-ka B-cell ayaa shaaca ka qaaday in daawaynta hore ay bixin karto heerarka badbaadada oo la hagaajiyay iyo waxyeellooyin yar, taasoo taageeraysa isticmaalkeeda daawaynta safka labaad.
Daaweynta CAR-T waxay Muujineysaa Badbaadada iyo Waxtarka Bukaannada Kansarka ee qaba Cudurrada Is-difaaca ama Caabuqa
Daraasad dhowaan lagu daabacay gudaha Lafaha Lancet waxay muujinaysaa in daaweynta unugyada CAR-T ay tahay mid ammaan ah oo waxtar u leh daaweynta lymphoma iyo bukaanada myeloma badan kuwaas oo sidoo kale qaba cudurada difaaca jirka ama bararka, taasoo bixinaysa caddayn rajo leh oo loogu talagalay codsigeeda ballaaran.
Aragtiyo Horumarin ah oo ku saabsan Noocyada Hidde-sideyaasha ee Dadka Waaweyn ee B-ALL
Dib u eegis dhammaystiran oo ku saabsan Dhiig waxay iftiiminaysaa horumarkii ugu dambeeyay ee laga sameeyay fahamka noocyada hidde-sideyaasha ee dadka waaweyn ee B-cell Lymphoblastic Leukemia (B-ALL). Daraasaddu waxay sahamisaa kala duwanaanshaha bayoolojiga, saameynta caafimaad, iyo muhiimadda daawada saxda ah ee hagaajinta natiijooyinka bukaanka.
Daraasad Horumarineed ayaa Xaqiijisay Badbaadada iyo Waxtarka Daaweynta CAR-T ee CD19/CD20 ee r/r B-NHL
Tijaabo lagu sameeyay xarun badan oo wejiga 1aad ah oo laga sameeyay Shiinaha ayaa muujisay badbaado iyo waxtar rajo leh oo prizlon-cel ah, oo ah daaweyn laba-jibbaaran oo CD19/CD20 CAR-T ah, taasoo rajo cusub u ah bukaanada qaba lymphoma-ka unugyada B ee aan ahayn Hodgkin (r/r B-NHL).
Calaamadaha Cusub ee Bayoolajiga ayaa saadaaliyay Natiijooyinka Daaweynta CAR-T ee Daaweynta Myeloma-da badan
Daraasad dhowaan lagu daabacay gudaha Dhiig waxay aqoonsataa heerarka BCMA (sBCMA) ee milmi kara iyo mugga burooyinka dheef-shiid kiimikaadka (MTV) sida biomarkers suurtagal ah si loo saadaaliyo natiijooyinka daaweynta CAR-T ee bukaanada soo noqnoqda iyo kuwa aan firfircoonayn ee badan (RRMM), taasoo u gogol xaaraysa xeeladaha daaweynta shaqsiyeed.
Daaweynta CAR-T: Mustaqbal Ballanqaad leh oo loogu talagalay Cudurrada Unugyada T-Cell
Daaweynta CAR-T, oo asal ahaan ah horumar laga sameeyay kansarka unugyada B, ayaa muujinaysa rajo wanaagsan oo ku saabsan daaweynta kansarka unugyada T iyo kansarka unugyada T-cell ee ba'an ee lymphoblastic leukemia (T-ALL). Daaweyntan isbeddelka leh waxay wajaheysaa caqabado gaar ah laakiin tijaabooyinka caafimaad ee dhowaan la sameeyay waxay bixiyaan rajo xalal daaweyn cusub oo ku saabsan kansarka unugyada T.
Daraasad Horumarin ah oo lagu daabacay Dhiigga: Daaweynta CAR-T ee ku salaysan Nanobody-ka ee loogu talagalay Cudurka Myeloid Leukemia ee Ba'an
Kooxda Caafimaadka ee Lu Daopei waxay gaareen horumar hor leh oo ku saabsan daaweynta Cudurka Dhiigga ee Ba'an ee Myeloid Leukemia (AML) iyagoo daraasaddooda ku sameeyay daaweynta CAR-T ee ku salaysan nanobody-ka CD7, oo lagu daabacay joornaalka caanka ah. Dhiig.
Xannibaadayaasha Menin: Daawaynta Aasaasiga ah ee Cudurka Leukemia-da ee Ba'an
Horumarkii ugu dambeeyay ee ka hortagga Menin waxay bixiyaan fursado daaweyn oo rajo leh oo loogu talagalay cudurka 'myeloid leukemia' ee ba'an (AML), iyagoo bartilmaameedsanaya isbeddellada hidde-sidaha iyo bixinta rajo cusub oo loogu talagalay kiisaska adag.